摘要
近年开发了许多抗HBV核苷(酸)类新药,有些已经在国外上市,有些仍处于临床试验阶段。与国内临床上应用的抗HBV核苷(酸)类药物相比,这些新药具有抗病毒作用强、耐药发生率低、患者耐受性好等优点,但也存在一些问题,如停药后易复发、随着疗程延长产生耐药的趋势增加等。本文对抗HBV核苷(酸)类新药的研究进展进行综述,以使临床医生对核苷(酸)类新药有更加深入的了解,为慢性乙型肝炎患者的抗病毒治疗提供更多选择。
A number of novel nucleos（t）ide analogues against HBV have been developed in recent years, some of which have been marketed abroad and some are currently under clinical trials. As compared with anti-HBV nucleos（t）ide analogues used in clinical practice in China, the novel nucleos（t）ide analogues exhibit greater antiviral activity, lower incidence rate of drug resistance, better tole-rance in patients and other advantages, however, there remain some problems, such as a high risk of recurrence after these nucleos （t）ide analogues are discontinued and increased resistance rates as treatment is prolonged. This review focuses on the research advances in novel anti-HBV nucleos（t）ide analogues in hope that clinicians may have a deeper knowledge of nucleos（t）ide analogues so as to provide more options for antiviral therapy for patients with chronic hepatitis B.
出处
《传染病信息》
2014年第4期233-236,共4页
Infectious Disease Information
基金
上海市科委"科技创新行动计划"医学与农业领域重点项目(13401902100)
